2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on TNBC & HR+ MBC: Analysis & Comparison of 1st Line Options for PD-L1 +/- Cancers With(out) BRCA 1/2. Exploring the Optimal ET Agent to Combine With Palbociclib in the First-line Endocrine-sensitive Disease
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Ian Krop
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Ian Krop
703 views
July 13, 2020
Comments 0
Login to view comments.
Click here to Login
Breast